Subscribe to RSS
Endovascular Stenting for Malignant Obstruction of Superior Vena Cava: A Single-Center Experience Using the Body Floss TechniqueFunding This study was not supported by any funding.
Purpose Endovascular stenting is the treatment of choice for malignant obstruction of the superior vena cava (SVC) when rapid symptomatic relief is desired. Body floss technique is not routinely used during SVC stenting but has few advantages over single-access technique. We report our experience with stenting for malignant obstruction of the SVC using the body floss technique.
Materials and Methods Between March 2015 and March 2020, 25 patients (20 men, 5 women; median age, 65 years) with malignant SVC obstruction underwent endovascular stenting of the SVC. We retrospectively evaluated these patients for clinical and technical success rates, complications, recurrence-free survival, and overall survival.
Results Stent placement was successful in 24/25 patients (technical success: 96%). Clinical success was achieved in 23/25 (92%) patients. A mortality rate of 4% (1/25) was noted due to SVC rupture. Partial stent migration was noted in two patients (8%) and was treated by placing an additional overlapping stent. Incidental early stent thrombosis was seen in two patients within 8 hours of stent placement, but these patients showed symptom relief with anticoagulation. Follow-up imaging confirmed stent patency in all patients. Late stent occlusion due to tumor progression was seen in one patient. The primary patency rate was 88% (22/25). Overall median survival of 133 days was observed (range: 1–847 days).
Conclusion Endovascular stenting of the SVC for malignant obstruction using the body floss technique is associated with high technical and clinical success, and low rate of complications.
14 April 2021 (online)
© 2021. Indian Society of Vascular and Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Lepper PM, Ott SR, Hoppe H. et al. Superior vena cava syndrome in thoracic malignancies. Respir Care 2011; 56 (05) 653-666
- 2 Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990; 160 (02) 207-211
- 3 Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56 (07) 407-413
- 4 Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 2006; 29 (03) 319-322
- 5 Straka C, Ying J, Kong F-M, Willey CD, Kaminski J, Kim DWN. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus 2016; 5: 229
- 6 Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome–a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3 (08) 811-814
- 7 Kishi K, Sonomura T, Mitsuzane K. et al. Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology 1993; 189 (02) 531-535
- 8 Lanciego C, Pangua C, Chacón JI. et al. Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgenol 2009; 193 (02) 549-558
- 9 Uberoi R CIRSE Quality Assurance Guidelines for Superior Vena Cava Stenting in Malignant Disease. doi:10.1007/s00270-005-0284-9
- 10 Ganeshan A, Hon LQ, Warakaulle DR, Morgan R, Uberoi R. Superior vena caval stenting for SVC obstruction: current status. Eur J Radiol 2009; 71 (02) 343-349
- 11 Fagedet D, Thony F, Timsit J-F. et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol 2013; 36 (01) 140-149
- 12 Tanigawa N, Sawada S, Mishima K. et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998; 39 (06) 669-674
- 13 Rachapalli V, Boucher L-M. Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J 2014; 65 (02) 168-176
- 14 Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984; 2 (08) 961-969
- 15 Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356 (18) 1862-1869
- 16 Dinkel H-P, Mettke B, Schmid F, Baumgartner I, Triller J, Do D-D. Endovascular treatment of malignant superior vena cava syndrome: is bilateral Wallstent placement superior to unilateral placement?. J Endovasc Ther 2003; 10 (04) 788-797
- 17 Chang S-N, Chi N-H, Lee W-J, Hsu K-L, Chiang F-T, Tseng C-D. Cardiac tamponade after stenting for superior vena cava obstruction. Zhonghua Minguo Xinzangxue Hui Zazhi 2009; 25: 161-164
- 18 Taylor JD, Lehmann ED, Belli A-M. et al. Strategies for the management of SVC stent migration into the right atrium. Cardiovasc Intervent Radiol 2007; 30 (05) 1003-1009